BRAF V600E

BRAF codon 600 point mutation p.V600E detected by sequencing, PCR or mutation-specific immunohistochemistry; used as a predictive marker for BRAF/MEK inhibitor therapy across melanoma, thyroid, colorectal, lung and other cancers.

CI-BIO-00000018BRAF graph →NCIt C98342 Tumor-agnostic · 4 approval rows

Also calledp.V600E · BRAF V600E-mutant · c.1799T>A

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug + indication textRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Trametinib US FDA · May 29, 2013 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (24)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	37	31	6	—	1 / 21 / 6 / 8 / 1
Melanoma	31	29	2	—	0 / 19 / 2 / 10 / 0
Thyroid Gland Papillary Carcinoma	12	3	8

Derived

Drugs with predictive evidence (29)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	45	36	9	A	34 / 9	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +12
DabrafenibSmall Molecule	22	19	3	A	18 / 4	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
TrametinibSmall Molecule	20	19	1	A	18 / 0	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
CetuximabMonoclonal Antibody	12	6	6	A	6 / 5	Malignant Colorectal Neoplasm
PanitumumabMonoclonal Antibody	9	6	3	B	4 / 2	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	6	3	3	B	3 / 3	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	4	3	1	B	1 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
CobimetinibSmall Molecule	3	3	—	B	3 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
OxaliplatinSmall Molecule	2	—	2	B	0 / 2	Malignant Colorectal Neoplasm
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
SorafenibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
TovorafenibSmall Molecule	1	1	—	A	1 / 0	Childhood Low Grade Glioma
MEK Inhibitor RO4987655	1	—	1	B	—	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (92)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 92 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF V600E45
Vemurafenib	Childhood Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID3777 In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5902 Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC) PMID 28480077 · Kocsis et al., 2017 · Open in CIViC	civic
Irinotecan + Panitumumab + VemurafenibCombination	Cholangiocarcinoma
BRAF K601E + BRAF V600E1
Cobimetinib + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID11670 This clinical study was conducted with 30 patients with colorectal cancer harboring BRAF V600E (n = 29) or BRAF K601E (n=1) mutations, treated with a combination of cobimetinib and vemurafenib. Of the… (full text at CIViC) PMID 36409971 · Klute et al., 2022 · Open in CIViC	civic
BRAF Amplification + BRAF V600E1
Selumetinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	E	Supports Resistance	4	accepted	EID92 COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF … (full text at CIViC) PMID 21098728 · Corcoran et al., 2010 · Open in CIViC	civic
ARAF S490T + BRAF V600EBRAF ARAF1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID1905 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient h… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic
BRAF V600E + GNAS R201CBRAF GNAS1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID1906 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient a… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (364)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Capecitabine	US FDA	Malignant Colorectal Neoplasm	treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.	approved	Apr 30, 1998	openfda
Capecitabine	US FDA	—	Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen.	approved	Apr 30, 1998	openfda
Capecitabine	US FDA	Pancreatic Adenocarcinoma	Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.	approved	Apr 30, 1998	openfda
Capecitabine

1 record matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (473)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 247 recruiting · 84 active phase 3 · 2,296 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 151–200 of 473 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06797336	A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors	recruiting	Phase 1	240	PAQ Therapeutics, Inc.INDUSTRY	2	Aug 12, 2026	clinicaltrials
NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	Phase 1 / Phase 2	75	National Cancer Institute (NCI)NIH	1	Aug 11, 2026	clinicaltrials
NCT02320435	A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial	active not recruiting	Phase 3	154	Hoffmann-La RocheINDUSTRY	15	Aug 11, 2026	clinicaltrials
NCT02884648	Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery	active not recruiting	Phase 2	35	M.D. Anderson Cancer CenterOTHER	1	Aug 11, 2026	clinicaltrials
NCT03392246	A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer	active not recruiting	Phase 2	25	Dana-Farber Cancer InstituteOTHER	1	Aug 11, 2026	clinicaltrials
NCT04526782	ENCOrafenib With Binimetinib in bRAF NSCLC(ENCO-BRAF)	active not recruiting	Phase 2	119	Intergroupe Francophone de Cancerologie ThoraciqueOTHER	1	Aug 11, 2026	clinicaltrials
NCT04675710	Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	active not recruiting	Phase 2	30	M.D. Anderson Cancer CenterOTHER	1	Aug 11, 2026	clinicaltrials
NCT04837716	Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer	active not recruiting	Phase 1	12	M.D. Anderson Cancer CenterOTHER	1	Aug 11, 2026	clinicaltrials
NCT06666348	Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK(MIRV)	recruiting	Phase 1 / Phase 2	50	St. Justine's HospitalOTHER	1	Aug 11, 2026	clinicaltrials
NCT07071714	A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer	active not recruiting	Phase 2	103	Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY	1	Aug 11, 2026	clinicaltrials
NCT02231775	Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	active not recruiting	Phase 2	58	M.D. Anderson Cancer CenterOTHER	1	Aug 10, 2026	clinicaltrials
NCT06269978	Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer	active not recruiting	Phase 1	9	Arjun MittraOTHER	1	Aug 10, 2026	clinicaltrials
NCT05502393	A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors	active not recruiting	Phase 1	133	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	Aug 7, 2026	clinicaltrials
NCT01837862	A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas	active not recruiting	Phase 1 / Phase 2	10	Julie KrystalOTHER	1	Aug 6, 2026	clinicaltrials
NCT04356729	A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma	active not recruiting	Phase 2	30	F. Stephen Hodi, MDOTHER	1	Aug 5, 2026	clinicaltrials
NCT04999761	AB122 Platform Study	recruiting	Phase 1	917	Taiho Pharmaceutical Co., Ltd.INDUSTRY	1	Aug 5, 2026	clinicaltrials
NCT05564403	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	active not recruiting	Phase 2	66	National Cancer Institute (NCI)NIH	1	Aug 4, 2026	clinicaltrials
NCT05579366	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01)	recruiting	Phase 1 / Phase 2	884	GenmabINDUSTRY	3	Aug 4, 2026	clinicaltrials
NCT06358430	Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)	active not recruiting	Phase 1	10	M.D. Anderson Cancer CenterOTHER	1	Aug 4, 2026	clinicaltrials
NCT07737600	A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer	not yet recruiting	Phase 1 / Phase 2	316	Lepu Biopharma Co., Ltd.INDUSTRY	1	Aug 4, 2026	clinicaltrials
NCT07745296	Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer(SAFIR-IMPACT)	not yet recruiting	Phase 3	990	UNICANCEROTHER	0	Aug 4, 2026	clinicaltrials
NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	Phase 1 / Phase 2	370	Revolution Medicines, Inc.INDUSTRY	1	Aug 3, 2026	clinicaltrials
NCT03091257	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	active not recruiting	Phase 1	30	Massachusetts General HospitalOTHER	1	Jul 31, 2026	clinicaltrials
NCT05063552	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	active not recruiting	Phase 2 / Phase 3	430	National Cancer Institute (NCI)NIH	1	Jul 31, 2026	clinicaltrials
NCT05217446	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer(SEAMARK)	active not recruiting	Phase 2	108	PfizerINDUSTRY	15	Jul 31, 2026	clinicaltrials
NCT05382559	A Study of ASP3082 in Adults With Advanced Solid Tumors	recruiting	Phase 1	681	Astellas Pharma IncINDUSTRY	7	Jul 31, 2026	clinicaltrials
NCT06965114	Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia	recruiting	Phase 1 / Phase 2	84	National Cancer Institute (NCI)NIH	1	Jul 31, 2026	clinicaltrials
NCT04657068	A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors	recruiting	Phase 1 / Phase 2	542	Artios Pharma LtdINDUSTRY	4	Jul 30, 2026	clinicaltrials
NCT05464030	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)	active not recruiting	Phase 1	220	EMD Serono Research & Development Institute, Inc.INDUSTRY	5	Jul 30, 2026	clinicaltrials
NCT03785249	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	active not recruiting	Phase 1 / Phase 2	731	Mirati Therapeutics Inc.INDUSTRY	2	Jul 29, 2026	clinicaltrials
NCT06219941	AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2	recruiting	Phase 2	226	AstraZenecaINDUSTRY	14	Jul 29, 2026	clinicaltrials
NCT06764771	A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors	recruiting	Phase 1	437	Bristol-Myers SquibbINDUSTRY	3	Jul 29, 2026	clinicaltrials
NCT07411599	Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")	recruiting	Phase 1 / Phase 2	28	M.D. Anderson Cancer CenterOTHER	1	Jul 28, 2026	clinicaltrials
NCT03181100	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer	active not recruiting	Phase 2	50	M.D. Anderson Cancer CenterOTHER	1	Jul 24, 2026	clinicaltrials
NCT03768063	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMbrella B)	active not recruiting	Phase 3	1,000	Hoffmann-La RocheINDUSTRY	24	Jul 24, 2026	clinicaltrials
NCT04776655	Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB(LIBImAb)	active not recruiting	Phase 3	280	Azienda USL Reggio Emilia - IRCCSOTHER_GOV	1	Jul 24, 2026	clinicaltrials
NCT07094893	Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status(ARIEL-ENGIC)	not yet recruiting	Phase 4	280	Gruppo Oncologico del Nord-OvestOTHER	0	Jul 24, 2026	clinicaltrials
NCT07582315	A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)	recruiting	Phase 3	538	Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY	1	Jul 24, 2026	clinicaltrials
NCT07606599	A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure	recruiting	Phase 3	398	Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY	1	Jul 24, 2026	clinicaltrials
NCT05719558	A Study of ASP1002 in Adults for Treatment of Solid Tumors	recruiting	Phase 1	798	Astellas Pharma Global Development, Inc.INDUSTRY	1	Jul 23, 2026	clinicaltrials
NCT05836324	A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	recruiting	Phase 1	570	Incyte CorporationINDUSTRY	9	Jul 23, 2026	clinicaltrials
NCT06974110	Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors	recruiting	Phase 1	132	MOMA TherapeuticsINDUSTRY	2	Jul 23, 2026	clinicaltrials
NCT07172919	A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation	recruiting	Phase 2	14	AmgenINDUSTRY	9	Jul 23, 2026	clinicaltrials
NCT07500298	Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer	recruiting	Phase 1	41	M.D. Anderson Cancer CenterOTHER	1	Jul 23, 2026	clinicaltrials
NCT06131840	A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	recruiting	Phase 1	914	Seagen, a wholly owned subsidiary of PfizerINDUSTRY	10	Jul 22, 2026	clinicaltrials
NCT06179160	A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	recruiting	Phase 1	710	Incyte CorporationINDUSTRY	8	Jul 22, 2026	clinicaltrials
NCT07318805	A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors	recruiting	Phase 1	260	PfizerINDUSTRY	1	Jul 22, 2026	clinicaltrials
NCT07340567	Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test(CIRCULATEIII)	active not recruiting	Phase 3	2,450	UNICANCEROTHER	2	Jul 22, 2026	clinicaltrials
NCT01933932	Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC(SELECT-1)	active not recruiting	Phase 3	510	AstraZenecaINDUSTRY	26	Jul 21, 2026	clinicaltrials
NCT05238922	Study of INCB123667 in Subjects With Advanced Solid Tumors	active not recruiting	Phase 1	291	Incyte CorporationINDUSTRY	8	Jul 21, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (24)

Drugs with predictive evidence (29)

Predictive evidence items (92)

Approvals mentioning the linked drugs (364)

Active trials (473)

Linked publications (85)